The Vitamin Harvard Quietly Buried

Berg states that the common RDA (400-800 IU) is far too low and that 10,000 IU daily is the baseline for health. He references the immune system's widespread vitamin D receptors and its role in fighting inflammation, cancer, and viruses. He dismisses studies that show no benefit by pointing out their tiny doses, implying that big pharma influences trial design to keep the vitamin from gaining credibility. For people who cannot get daily sun, 10,000 IU via supplement or a tablespoon of cod liver oil is presented as a practical alternative.

Berg challenges the public health messaging that sun avoidance is universally beneficial. He traces the origins of sun phobia to dermatology companies that sold synthetic vitamin D while suppressing the free natural alternative. He says that prior to antibiotics, sanitariums around the world used controlled sunbathing to combat TB. He also asserts that the most lethal skin cancer, melanoma, frequently appears on body parts that never see the sun, indicating a causal role of vitamin D deficiency. Thus, sensible sun exposure is reclaimed as a vital health practice rather than a danger.

Berg highlights the work of Dr. Coimbra, which he learned about in a recent interview. The protocol rests on the concept of ‘vitamin D resistance’ — certain individuals have genetically impaired D receptors or enzymatic defects, meaning standard serum levels do not reflect tissue activity. By pushing doses far above the norm, the protocol saturates those resistant receptors, restoring immune regulation. Berg says the protocol yields ‘90 percentile’ effectiveness, positioning it as a game changer for autoimmune patients who have few effective, non-immunosuppressive options.

Berg emphasizes that without testing, one cannot know if they are truly sufficient because blood levels might not reflect intracellular availability. He explicitly recommends aiming for at least 50 ng/mL. He offers a linked home test kit that uses a blood spot on filter paper, bypassing the need for a doctor's appointment. This aligns with his broader theme of empowering individuals to take control of their health outside the conventional medical system.

Berg argues that vitamin D is a profound threat to big pharma because it can inexpensively address many conditions treated with lucrative drugs. Harvard, heavily funded by pharma, cannot afford to publicize this. He ties this to a campaign by two dermatology companies (Leoarma and Elmroll) that developed synthetic vitamin D products while promoting sun avoidance. The 'disinformation playbook' (five pillars: fake trials, blitzing scientists, diversion, screen, fix) explains how this system operates. Dr. William Grant, cited by Berg, states that government-sponsored RCTs are designed on drug models, not nutrient models, guaranteeing they show no benefit. The result is a controversy manufactured to protect profits.

Berg recounts an interview with Dr. Coimbra, who explained that genetic defects in vitamin D receptors or activation can prevent the hormone from entering cells, leading to persistent deficiency. There is currently no clinical test that reveals tissue-level vitamin D status. Therefore, people with autoimmune diseases or chronic inflammation may need much higher doses than the general population to overcome this resistance. This insight underpins the rationale for the Coimbra protocol and Berg's insistence on targeting at least 50 ng/mL in blood, which he sees as a minimum for ensuring tissue saturation.

Berg says that both Leoarma and Elmroll developed past products with synthetic vitamin D—one combined with a corticosteroid, another as pure vitamin D—targeted at skin problems. Simultaneously, they promoted the idea that sun causes skin cancer, creating a lucrative market. Berg then argues that the most dangerous skin cancer (melanoma) often appears in sun-protected areas and is actually linked to vitamin D deficiency, not sun exposure. This inversion suggests the demonization of the sun was a strategic maneuver to replace a free natural source with a patented pharmaceutical alternative.